% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • oprahisapig oprahisapig Apr 4, 2013 10:15 PM Flag

    Oppenheimer reiterates $2 price target

    Zalicus (NASDAQ: ZLCS) had its outperform rating reaffirmed by analysts at Oppenheimer. They currently have a $2.00 price target on the stock. The analysts wrote, “Investors remain focused on the two ongoing Z160 Phase IIa proof-of-concept studies in chronic neuropathic pain. Zalicus now expects to report top-line data from these studies by late-2H13. As a reminder, the two Phase IIa studies include Lumbosacral Radiculopathy (LSR) and Postherpetic Neuralgia (PHN). Zalicus stated that it will continue the clinical development of Z944 in 2013. A key US patent was issued in February 2013 that provides coverage through April 2029. We believe that, with total cash of $36.4M at YE12, Zalicus is capitalized past data readout of its two Z160 Phase IIa studies and into 2014.”

    SortNewest  |  Oldest  |  Most Replied Expand all replies